Ganga Pharmaceuticals Ltd - 539680 - Intimation For 34Th Annual General Meeting Scheduled To Be Held On Saturday, September 16, 2023
Intimation for 34th Annual General Meeting scheduled to be held on Saturday, September 16, 202307-08-2023
07-08-2023
Ganga Pharmaceuticals Ltd - 539680 - Board Meeting Outcome for Outcome Of The Board Meeting Held Today Ie On Monday, August 07,2023
Outcome of the Board Meeting held today ie on Monday, August 07,202307-08-2023
Ganga Pharmaceuticals Ltd - 539680 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended June 30,202307-07-2023
Ganga Pharmaceuticals Ltd - 539680 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Non applicability of Annual Secretarial Compliance Report for the year ended March 31, 202324-05-2023
Ganga Pharmaceuticals Ltd - 539680 - Disclosure Of Related Party Transactions Pursuant To Regulations 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Disclosure of Related Party Transactions on a Standalone basis for the half year ended March 31, 2023.18-05-2023
Ganga Pharmaceuticals Ltd - 539680 - Board Meeting Outcome for Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Held On Thursday, May 18, 2023 May 18, 2023
This is to inform you that the Board of Directors of the Company at its meeting held today i.e., on May 18, 2023 (commenced at 2.15 p.m. and concluded at 2.45 p.m.) have inter- alia considered and approved; 1. Audited Financial results for the half and financial year ended on March 31, 2023, in this regard, please find enclosed herewith: : (@) Audited Financial Results of the Company for the half and financial year ended on March 31,2023, (b) Auditor''s Report in respect of the Audited Financial Results of the Company for the financial year ended March 31, 2023.18-05-2023
Ganga Pharmaceuticals Ltd - 539680 - Outcome Of The Board Meeting On May 18, 2023
Outcome of the Board Meeting on May 18, 2023 for Audited Financial results for the half and financial year ended on March 31, 2023,18-05-2023
Ganga Pharmaceuticals Ltd - 539680 - Board Meeting Intimation for To Consider And Approve The Audited Financial Results Of The Company For The Half And Financial Year Ended March 31, 2023.
Ganga Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2023 ,inter alia, to consider and approve the Audited Financial Results of the company for the Half and Financial Year ended March 31, 2023.08-05-2023
Ganga Pharmaceuticals Ltd - 539680 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGanga Pharmaceuticals Ltd 2CIN NO.L99999MH1989PLC053392 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 1.82 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Priti Kothari Bhaiya Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Anagh B Sharma Designation: Chief Financial Officer EmailId: [email protected] Date: 25/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.25-04-2023
Ganga Pharmaceuticals Ltd - 539680 - Submission Of Certificate Under Clause 40(10) Of SEBI (LODR) Regulation, 2015 For The Year Ended On March 31, 2023.
Submission of certificate under clause 40(10) of SEBI (LODR) Regulation, 2015 for the year ended on March 31, 2023.10-04-2023